Status:
COMPLETED
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
Immune Tolerance Network (ITN)
Conditions:
Kidney Transplantation
Kidney Failure, Chronic
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant. Th...
Detailed Description
All patients receiving an organ or tissue transplant must take special medicines known as "immunosuppressive drugs" in order to prevent the immune system from rejecting the transplant. These drugs can...
Eligibility Criteria
Inclusion
- Awaiting first or second transplant with a living donor or first transplant with a cadaveric donor
- For living-donor transplants, must have one or more HLA antigen-mismatched donors identified
- Serologic evidence of prior exposure to Epstein-Barr virus (EBV)
Exclusion
- ABO blood group-incompatibility for a kidney graft of tissue from a donor
- Decreased circulating white blood cell count
- Positive for HIV-1, hepatitis B and C viruses
- Have had prior radiation therapy that could limit dose
- Lung capacity \<50% of predicted normal
- Evidence of insufficient cardiac capacity
- Unwilling to use adequate contraception until 2 years after transplant
- Lactation or pregnancy
- Presence of antibody against the donor
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00801632
Start Date
December 1 2008
End Date
November 1 2014
Last Update
November 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114